WO2000025827A2 - Dna molecules encoding muc-1 and use thereof in tumor vaccination - Google Patents

Dna molecules encoding muc-1 and use thereof in tumor vaccination Download PDF

Info

Publication number
WO2000025827A2
WO2000025827A2 PCT/EP1999/007874 EP9907874W WO0025827A2 WO 2000025827 A2 WO2000025827 A2 WO 2000025827A2 EP 9907874 W EP9907874 W EP 9907874W WO 0025827 A2 WO0025827 A2 WO 0025827A2
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
dna
composition according
fragment
pharmaceutical composition
Prior art date
Application number
PCT/EP1999/007874
Other languages
French (fr)
Other versions
WO2000025827A3 (en
Inventor
Dino Parente
Anna Maria Di Massimo
Rita De Santis
Original Assignee
Menarini Ricerche S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002348745A priority Critical patent/CA2348745A1/en
Application filed by Menarini Ricerche S.P.A. filed Critical Menarini Ricerche S.P.A.
Priority to BR9914892-7A priority patent/BR9914892A/en
Priority to EA200100395A priority patent/EA200100395A1/en
Priority to PL99348156A priority patent/PL348156A1/en
Priority to AU11522/00A priority patent/AU1152200A/en
Priority to JP2000579265A priority patent/JP2002528519A/en
Priority to HU0103784A priority patent/HUP0103784A2/en
Priority to EP99971329A priority patent/EP1124956A2/en
Priority to MXPA01004186A priority patent/MXPA01004186A/en
Priority to SK571-2001A priority patent/SK5712001A3/en
Publication of WO2000025827A2 publication Critical patent/WO2000025827A2/en
Publication of WO2000025827A3 publication Critical patent/WO2000025827A3/en
Priority to BG105458A priority patent/BG105458A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the invention relates to a pool of DNA plasmid constructs containing the sequences of human MUC-1 encoding fragments and to a pool of DNA plasmids in which the fragments themselves are preceded by the sequence encoding a protein consisting of human ubiquitin fused to a bacterial Lad fragment.
  • the invention further relates to their use in the preparation of pharmaceutical compositions for use as DNA anti-tumor vaccines.
  • the invention provides an anti-tumor therapy based on the induction or activation of the immune response able to bring about tumor rejection.
  • the validity of such an idea is demonstrated from the first clinical results; for example, patients treated with a viral vaccine containing the Carcinoembryonic Antigen (CEA) encoding sequences demonstrated immune system activation against this antigen (Tsang KY et al . J. Natl. Cancer. Inst . 87: 982, 1995).
  • CEA Carcinoembryonic Antigen
  • an immune anti-tumor response is achievable through four different approaches: a) Ex vivo engineering of patient tumor cells in order to make them more immunogenic and suitable as a vaccine; b) Ex vivo engineering of patient immune cells in order to pre-activate an in vi tro immune response. c) Inoculation of naked or liposome capsulated or viral particle integrated (retrovirus, vaccinia virus, adenovirus, etc.) DNA encoding tumor associated antigens; d) Treatment with recombinant or synthetic soluble tumor antigens conjugated or mixed with adjuvants.
  • the first two approaches consist of the engineering of every single patient cell and are limited in that they are necessarily patient-specific, while the latter two are aimed to obtain products comparable to a traditional drug.
  • the new vaccination methods reflect the development of new technologies.
  • Muscle cells express class I MHC antigens at low levels only, and do not apparently express class II antigens or co-stimulatory molecules. Consequently, transfected muscle cells are unlikely to play an important role in the onset of the immune response per se.
  • Antigen Presenting Cells such as macrophages or dendritic cells
  • APC Antigen Presenting Cells
  • macrophages or dendritic cells play a fundamental role in capturing the myocyte released antigen and in the subsequent processing and presenting of the respective peptides in the context of the class I and II molecules, thus inducing a CD8+ cell activation with cytotoxic activity as well as activation of the CD4+ cells co-operating with B lymphocytes in eliciting the antibody response
  • cytokines is known to improve the therapeutic effect deriving from immunization with DNA.
  • Cytokines can be administered in the form of exogenous proteins as reported in Irvine et al . , J. Immunol . 156: 238, 1996.
  • An alternative approach is represented by the contemporaneous inoculation of both the tumor antigen or the desired cytokine encoding plasmids, thus allowing the cytokine to be produced in si tu (Kim JJ et al . Immunol 158 : 816, 1997) .
  • MUC-1 is an epithelial luminal surface glycoprotein (Patton S . et al . BBA 1241 : 407, 1995) . In the cell transformation process this glycoprotein loses the apical localization and its expression level rises dramatically.
  • the protein function consists of protecting the luminal surfaces, for example in the mammal gland, ovary, endometrium, colon, stomach, pancreas, bladder, kidney, etc.
  • a glycosylation defect is reported that makes tumor cell associated MUC-1 antigenically different from normal cell associated MUC-1. This phenomenon causes tumor MUC-1 to expose the antigen epitopes that are normally masked by the sugar moieties in the normal cell expressed MUC-1. This characteristic makes tumor MUC-1 particularly interesting in an induction of a tumor specific antibody response (Apostolopoulos V. et al . Cri t . Rev. Immunol . 14 :293, 1994) .
  • the vaccination is aimed at inducing immune responses against tumor cells expressing MUC1 at high levels, preserving at the same time the low expressing normal epithelia.
  • the DNA vaccination relies upon the entrance of a gene or portions thereof inside the body cells followed by transcription and translation of the inserted sequence and thus the intracellular synthesis of the corresponding polypeptide.
  • An important advantage of this system is that the neo-synthesized protein is naturally processed inside the cell and the produced peptides are associated with the Major Histocompatibility Complex class I molecules (MHC-I) .
  • MHC/peptide complexes are therefore naturally exported to the cell surface where they can be recognized by the immune system CD8+ cytotoxic cells.
  • the invention relates particularly to a pharmaceutical composition containing one or more DNA encoding Mucin (MUC-1) protein fragments .
  • the DNA used in the present invention can be plasmid or viral DNA, preferably plasmid DNA obtained employing the pMRS30 expression vector described in fig. 13.
  • compositions according to the invention contain preferably at least two DNA fragments of the Mucin (MUC-1) or of another protein overexpressed in tumor cells.
  • compositions according to the invention contain preferably at least four fragments, each ranging from 200 to about 700 nucleotides, each sequence being juxtaposed and possibly partially overlapping, from about 50 to about 150 nucleotides, at the 3' and/or 5' end of the adjacent one.
  • the DNA fragments according to the invention can be possibly preceded at the 5' end by a ubiquitin encoding DNA sequence and possibly also by a Lad portion of Escherichia coli .
  • the invention relates also to new DNA fragments and to the use of Mucin-1 fragments defined above in the medicine and anti- tumor vaccine preparation.
  • Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS166 expression vector.
  • This DNA includes the sequence corresponding to nucleotides 136-339 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by the two translation stop codons, TGA and TAA.
  • the encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 136-339 fragment of the EMBL sequence J05581.
  • Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS169 expression vector.
  • This DNA includes the sequence corresponding to nucleotides 205-720 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA.
  • the encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 205-720 fragment of the EMBL sequence J05581.
  • Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS168 expression vector.
  • This DNA includes the sequence corresponding to nucleotides 631-1275 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA.
  • the encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 631-1275 fragment of the EMBL sequence J05581.
  • Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS167 expression vector.
  • This DNA includes the sequence corresponding to nucleotides 1222-1497 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA.
  • the encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 1222-1497 fragment of the EMBL sequence J05581.
  • Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS175 expression vector.
  • This DNA includes the sequence corresponding to nucleotides 136-1497 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA.
  • the encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 136-1497 fragment of the EMBL sequence J05581.
  • Nucleotide DNA sequence (with the respective amino acid sequence) termed UBILacI .
  • the encoded polypeptide includes the ubiquitin sequence fused to a partial sequence of the bacterial protein beta-galactosidase, as described in Chau V. et al .
  • Fig. 7 Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the expression vector pMRS30 to give the pMRS171 expression vector.
  • This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence corresponding to nucleotides 136-339 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA.
  • the coded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 136-339 of the EMBL sequence J05581.
  • Fig. 7 Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the expression vector pMRS30 to give the pMRS171 expression vector.
  • This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence corresponding to nucleotides 136-339 of the EMBL sequence J05
  • Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS174 expression vector.
  • This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 205-720 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA.
  • the encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 205-720 of the EMBL sequence J05581.
  • Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS173 expression vector.
  • This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 631-1275 of the EMBL sequence J05581 followed by two translation stop codons, TGA and
  • the encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 631-1275 of the EMBL sequence J05581.
  • Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS172 expression vector.
  • This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 1222-1497 of the EMBL sequence J05581 followed by two translation stop codons, TGA and
  • the encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 1222-1497 of the EMBL sequence J05581.
  • Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS176 expression vector.
  • This DNA includes the sequence named UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 136-1497 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA.
  • the encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 136-1497 of the EMBL sequence J05581.
  • the 1- 2862 region corresponds to the Accl (location 504) - BamHI (location 3369) region of the pSV2CAT vector (EMBL M77788) ;
  • the 2863-3721 region includes the human cytomegalovirus promoter (human cytomegalovirus major immediate-early gene enhancer) ;
  • the 3722-4905 region includes several cloning sites, including Xbal (location 3727) , and the processing signal of the rabbit beta- globin gene.
  • a DNA plasmid pool encoding, in eukaryotic cells, fragments of the MUC-1 human protein antigen was prepared. Constructs are based on the mammalian expression vector termed pMRS30, described in figure 13 and previously claimed in the Patent Application W095/11982, and contain partial sequences of the MUC-1 cDNAs reported in the EMBL database with accession number J05581. MUC-1 encoding DNA was fragmented so that each fragment represents a discrete portion, partially overlapping to the adjacent ones. Administration of a mix of such plasmids can cause different plasmids to transfect different APC cells at the administration site. Therefore such cells produce and process discrete portions of the MUC-1 protein giving the related peptides.
  • the occurring subdominant and cryptic peptides can also be presented in association with class I MHC molecules thus generating a cytotoxic immune response.
  • the present invention thus relates to the use of a group of four constructs ( Figures 1 to 4) containing MUC-1 cDNA partial fragments in admixture containing at least two of them and a group of four constructs ( Figures 7 to 10) containing MUC-1 cDNA partial fragment preceded by the DNA encoding a protein sequence containing Ubiquitin and an Escherichia coli Lac I portion ( Figure 6) used separately or in admixture containing at least two of them.
  • the present invention relates also to the use of the construct ( Figure 5) containing the almost complete sequence of the MUC-1 cDNA and the construct ( Figure 11) containing the almost complete sequence of the MUC-1 cDNA preceded by the DNA encoding a protein sequence containing Ubiquitin and an Escherichia coli Lac I portion.
  • the mixture of the four constructs containing the partial fragments of the MUC-1 cDNA and the mixture of the four constructs containing the partial fragments of the MUC-1 cDNA preceded by the DNA encoding a protein sequence, containing Ubiquitin and an Escherichia coli Lac I portion, represents a preferred embodiment of the present invention.
  • Constructs according to the present invention can be used in the anti-tumor therapy of patient affected with tumors characterized by high MUC-1 expression.
  • Constructs described in the present invention were obtained as follows.
  • the fragments of the MUC-1 DNA were obtained by RT-PCR from BT20 cell line or by DNA partial chemical synthesis. Such fragments were then cloned into the pMRS30 expression vector and verified by sequencing.
  • the fragments were obtained from the first series of constructs by a PCR re-amplification. These fragments were then fused to the DNA encoding the Ubiquitin (obtained by RT-PCR from MCF7 cell line mRNA) and a partial lad sequence (obtained by PCR from the commercial vector pGEX) .
  • fragments or constructs according to the invention are suitably formulated, using carriers and methods previously employed in naked DNA vaccines, as described for example in The Immunologist, 1994, 2:1; WO 90/11092, Proc . Natl. Acad. Sci . U.S.A., 1986, 83, 9551; US 5580859; Immunology today 19 (1998), 89-97); Proc. Natl. Acad. Sci. U.S.A. 90 (1993), 11478-11482; Nat. Med. 3 (1997), 526-532; Vaccine 12 (1994), 1495-1498; DNA Cell. Biol.
  • the dosages will be determined on the basis of clinical and pharmacological-toxicological trials. Generally speaking, they will be comprised between 0.005 ⁇ g/kg and 5 ⁇ g/kg of the fragment mix.
  • the composition of the invention can also contain a cytokine or a cytokine encoding plasmid.
  • Example 1 Plasmid pMRSl ⁇ construction.
  • BT20 tumor cells (ATCC HTB-19) were cultured in Eagles MEM supplemented with 10% fetal calf serum. Ten million cells were trypsinized, washed with PBS, and mRNA extracted.
  • RNA was subjected to RT-PCR (reverse transcriptase-polymerase chain reaction) reaction in the presence of the following synthetic oligonucleotides :
  • VI1 (5 GATCTCTAGAATGACAGGTTCTGGTCATGCAAGC 3)
  • V4 (5 GATCTCTAGAAAGCTTATCAACCTGAAGCTGGTTCCGTGGC 3)
  • the resulting pMRS166 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the nucleotides 136-339 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
  • RNA obtained as reported in example 1 was amplified by RT-PCR in the presence of the following synthetic oligonuclotides :
  • the whole fragment was thus cloned in the Xbal site of the pMRS30 expression vector.
  • the resulting pMRS169 vector contains a DNA fragment including the ATG codon, the sequence partially corresponding to the nucleotides 205-720 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
  • RNA obtained as reported in example 1 was amplified by RT-PCR in the presence of the following synthetic oligonuclotides :
  • VI3 (5 GATCTCTAGAATGGGCTCAGCTTCTACTCTGGTGCACAACGGC 3)
  • V8 (5 GATCTCTAGAAAGCTTATCACAAGGCAATGAGATAGACAATGGCC 3)
  • the produced DNA fragment, purified and digested with the restriction enzyme Xbal was cloned in the pMRS30 expression vector.
  • the resulting pMRS168 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the nucleotides 631-1275 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
  • Example 4 Plasmid pMRS167 construction. An aliquot of the RNA obtained as reported in example 1 was subjected to RT-PCR reaction in the presence of the following synthetic oligonucleotides :
  • the produced DNA fragment, purified and digested with the restriction enzyme Xbal was cloned in the pMRS30 expression vector.
  • the resulting pMRS167 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the nucleotides 1222-1497 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
  • Example 5 Plasmid pMRS175 construction. pMRS166, 169, 168, 167 plasmids were subjected to PCR reaction in the presence of the following nucleotide pairs: VI1 (see example 1)
  • V21 (5 GGCTCAGCTTCTACTCTGGTGCACAACGGC 3)
  • V22 (5 CAAGGCAATGAGATAGACAATGGCC 3) for pMRS168
  • V23 (5 CTGGTGCTGGTCTGTGTTCTGGTTGCG 3)
  • the four DNA fragments obtained in the respective PCR reactions were mixed in equimolar amounts and PCR reacted in the presence of the Vll and V10 oligonuclotides.
  • the resulting pMRS175 vector contains a DNA fragment including the ATG codon, the sequence partially corresponding to the nucleotides 136-1497 of the EMBL sequence J05581 and two stop codons TGA and TAA.
  • Example 6 Plasmid pMRS171 construction.
  • MCF7 tumor cells (ATCC HTB-22) were cultured in Eagles MEM supplemented with 10% fetal calf serum. Ten million cells were trypsinized, washed with PBS, and mRNA extracted.
  • DNA from pGEXHT (Pharmacia) was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:
  • LacIdown (5GATCGGATCCTCGGGAAACCTGTCGTGCCAGCTGC 3) This reaction gives a DNA fragment termed fragment 2.
  • the resulting pMRS156 vector contains a DNA fragment including the sequence encoding the ubiquitin fused to the sequence encoding a bacterial beta-galactosidase portion. This fragment, termed UBILacI, is reported in fig. 6.
  • Plasmid pMRS166 DNA was subjected to a PCR reaction in presence of the following synthetic oligonucleotides: V3 (5GATCGGATCCACAGGTTCTGGTCATGCAAGC 3) V4 (see Example 1)
  • V3 5GATCGGATCCACAGGTTCTGGTCATGCAAGC 3
  • V4 see Example 1
  • the resulting fragment was cloned into the pMRS30 expression vector.
  • the resulting pMRS171 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 136-339 nucleotides of the EMBL sequence J05581 and two stop codons, TGA and TAA. This fragment is reported in fig. 7.
  • Plasmid pMRS174 construction Plasmid pMRS169 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides: V5 (5GATCGGATCCGTGCCCAGCTCTACTGAGAAGAATGC 3) V6 (5GATCTCTAGAAAGCTTATCAGCTGGGAATTGAGAATGGAGTGCTCTTGC 3) The produced DNA fragment, purified and digested with the restriction enzymes Xbal and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from the pMRS156 plasmid. The resulting fragment was cloned into the pMRS30 expression vector.
  • the resulting pMRS174 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 205-720 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 8.
  • Plasmid pMRS168 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:
  • V7 (5GATCGGATCCGGCTCAGCTTCTACTCTGGTGCACAACGGC 3)
  • V8 (see example 3)
  • the resulting fragment was cloned into the pMRS30 expression vector.
  • the resulting pMRS173 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 631-1275 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 9.
  • Plasmid pMRS167 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:
  • the resulting fragment was cloned into the pMRS30 expression vector.
  • the resulting pMRS172 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 1222-1497 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 10.
  • Plasmid pMRS167 DNA was subjected PCR reaction in the presence of the following synthetic oligonucleotides: V3 (see example 6)
  • the resulting fragment was cloned into the PMRS30 expression vector.
  • the resulting pMRS176 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 136-1497 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 11.
  • Example 11 Eukaryotic cell transfection and testing for transcriptio .
  • CHO (Chinese Hamster Ovary) cells were cultured in alpha MEM supplemented with ribonucleotides and deoxyribonucleotides at transfection time.
  • Dendritic cells were obtained from CD34+ hemopoietic precursors cultured in IMDM without serum, supplemented with GM- CSF, IL4, SCF, Fit3 and TNFalpha. After 7 days the obtained cell population was transfected.
  • Dendritic cells were obtained from monocytes isolated from PBMC (peripheral blood mononuclear cells) , cultured in RPMI supplemented with FCS, GM-CSF, and IL-4. After 7 days the obtained cell population was transfected. In each case, about one million cells were transfected with one of the plasmids reported in examples 1 to 10. Transfection was carried out using 3 ⁇ g of plasmid DNA and 4 ⁇ l of DMRIE (Gibco) by lipofection.
  • a mRNA aliquot was subjected to RT-PCR reaction in the presence of the oligonucleotide pair specific for the transfected DNA plasmid.
  • figure 12 reports the electrophoretic analysis of the DNA fragments obtained by RT-PCR from the mRNA of the three cell populations, transfected with the pMRS169 plasmid. In this case the oligonucleotide pair V12/V6 was used. Example 12. In vivo study results.
  • the in vivo studies were conducted using human MUCl transgenic C57BL mice. As a consequence in these animals the MUCl protein represents a self-protein.
  • the employed vaccination schedule consists of 3 intradermic (dorsal portion, 50 micrograms DNA for each side) administrations (at days 0, 14, 28) of 100 micrograms plasmid DNA. At day 14 after the last administration, the animals were sacrificed and sera were tested for anti-human mucin antibodies. The assayed fragment mixes, object of the present invention, stimulated a good immune response in the treated animals.
  • the two vaccinations differ in the type of the elicited antibody response.
  • the antibody titer results much more higher in the vaccination with 3XTR.
  • IgG subtypes are in favor of an essentially humoral (antibody) response in the case of vaccination with 3XTR, and of a cellular response (cytotoxic) in the case of vaccination with DNA.
  • cytotoxic a principally cytotoxic immune response is preferable. Because the experiments were carried out on transgenic mice, in whom the human mucin is "self", we can foresee a similar response in humans. This response could justify the use, as DNA vaccines, of the compounds of the present invention in the treatment of MUCl overxpressing human tumors .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein is a pharmaceutical composition containing one or more DNA molecules encoding fragments of a protein overexpressed in tumor cells, in order to induce an anti-tumor Ag-specific immune response, in association with suitable excipients and adjuvants.

Description

PHARMACEUTICAL COMPOSITION, CONTAINING FRAGMENTS OF AN ANTIGENIC PROTEIN ENCODING DNA ENDOWED WITH ANTI-TUMOR EFFECT.
Field of the invention The invention relates to a pool of DNA plasmid constructs containing the sequences of human MUC-1 encoding fragments and to a pool of DNA plasmids in which the fragments themselves are preceded by the sequence encoding a protein consisting of human ubiquitin fused to a bacterial Lad fragment. The invention further relates to their use in the preparation of pharmaceutical compositions for use as DNA anti-tumor vaccines.
Background art
The invention provides an anti-tumor therapy based on the induction or activation of the immune response able to bring about tumor rejection. The validity of such an idea is demonstrated from the first clinical results; for example, patients treated with a viral vaccine containing the Carcinoembryonic Antigen (CEA) encoding sequences demonstrated immune system activation against this antigen (Tsang KY et al . J. Natl. Cancer. Inst . 87: 982, 1995).
The activation of an immune anti-tumor response is achievable through four different approaches: a) Ex vivo engineering of patient tumor cells in order to make them more immunogenic and suitable as a vaccine; b) Ex vivo engineering of patient immune cells in order to pre-activate an in vi tro immune response. c) Inoculation of naked or liposome capsulated or viral particle integrated (retrovirus, vaccinia virus, adenovirus, etc.) DNA encoding tumor associated antigens; d) Treatment with recombinant or synthetic soluble tumor antigens conjugated or mixed with adjuvants.
The first two approaches consist of the engineering of every single patient cell and are limited in that they are necessarily patient-specific, while the latter two are aimed to obtain products comparable to a traditional drug.
The new vaccination methods reflect the development of new technologies. The recent indications coming from the experimentation on DNA naked vaccines that induce either a persistent antibody or a cell immune response, make the traditional protein subunit vaccines constituted of certain specific peptides, inducing a lymphocyte population, obsolete. Intramuscularly or intradermically injected proteins, encoded by naked DNA, induce a cytotoxic-specific response as well as a helper response. This powerful combination is extremely effective but the underling mechanism is not completely clarified yet. Muscle cells express class I MHC antigens at low levels only, and do not apparently express class II antigens or co-stimulatory molecules. Consequently, transfected muscle cells are unlikely to play an important role in the onset of the immune response per se. Recent data show that Antigen Presenting Cells (APC) , such as macrophages or dendritic cells, play a fundamental role in capturing the myocyte released antigen and in the subsequent processing and presenting of the respective peptides in the context of the class I and II molecules, thus inducing a CD8+ cell activation with cytotoxic activity as well as activation of the CD4+ cells co-operating with B lymphocytes in eliciting the antibody response (Corr M et al J. Exp. Med. 184 : 1555, 1996) ( Tighe, H. et al . Immunology Today 19 : 89, 1998) . Furthermore, the use of cytokines is known to improve the therapeutic effect deriving from immunization with DNA. Cytokines can be administered in the form of exogenous proteins as reported in Irvine et al . , J. Immunol . 156: 238, 1996. An alternative approach is represented by the contemporaneous inoculation of both the tumor antigen or the desired cytokine encoding plasmids, thus allowing the cytokine to be produced in si tu (Kim JJ et al . Immunol 158 : 816, 1997) .
The active immunization approach of the present invention is based on the use of DNA vectors as vaccines against the MUC-1 human antigen or Polymorphic Epithelial Mucin (PEM) , overexpressed in tumor cells. MUC-1 is an epithelial luminal surface glycoprotein (Patton S . et al . BBA 1241 : 407, 1995) . In the cell transformation process this glycoprotein loses the apical localization and its expression level rises dramatically. The protein function consists of protecting the luminal surfaces, for example in the mammal gland, ovary, endometrium, colon, stomach, pancreas, bladder, kidney, etc. A glycosylation defect is reported that makes tumor cell associated MUC-1 antigenically different from normal cell associated MUC-1. This phenomenon causes tumor MUC-1 to expose the antigen epitopes that are normally masked by the sugar moieties in the normal cell expressed MUC-1. This characteristic makes tumor MUC-1 particularly interesting in an induction of a tumor specific antibody response (Apostolopoulos V. et al . Cri t . Rev. Immunol . 14 :293, 1994) .
As an objective, the vaccination is aimed at inducing immune responses against tumor cells expressing MUC1 at high levels, preserving at the same time the low expressing normal epithelia. The DNA vaccination relies upon the entrance of a gene or portions thereof inside the body cells followed by transcription and translation of the inserted sequence and thus the intracellular synthesis of the corresponding polypeptide. An important advantage of this system is that the neo-synthesized protein is naturally processed inside the cell and the produced peptides are associated with the Major Histocompatibility Complex class I molecules (MHC-I) . The MHC/peptide complexes are therefore naturally exported to the cell surface where they can be recognized by the immune system CD8+ cytotoxic cells. Only the polypeptides synthesized inside the cell are then processed and presented in association with the MHC class I molecules, thus making it the only mechanism to stimulate, a specific cytotoxic response. Vaccination systems based on protein or peptide administration are usually more effective in stimulating the antibody immune response which, to date, has been shown to be ineffective in rejecting tumor cells. Current gene therapy techniques rely upon DNA packaging in recombinant viral vectors (retrovirus and adenovirus) . The naked DNA administration is much more advantageous in terms of effectiveness and safety compared to viral vector therapies (Kumar V and Sercarz E. Nature Med. 2 : 857, 1996; McDonnel WM et al . , New England J. of Med. 334 : 42, 1996) . In fact naked DNA is unable either to duplicate or integrate in the host tissue DNA and does not induce the immune response to viral proteins.
The use of the ubiquitin to enhance the neo-synthesized protein processing and thus cytotoxic lymphocyte induction was recently reported (Rodriguez F. et al . , J. Virology 71 : 8497 , 1997) . The use of ubiquitin in order to generate proteins with an N-terminal amino acid, making them unstable and thus prone to enhanced degradation, had been previously reported (Bechmair A. et al . , SCIENCE 234 : 179, 1986) . The higher instability of these proteins was subsequently related to enhanced intracellular processing and presentation of model proteins by MHC-1 (Grant E P et al . , J. Immunol . 155 : 3750, 1995) ( Wu Y and Kipps T. J. , J. Immunol . 159 : 6037, 1997) .
The use of single constructs containing partial antigen encoding DNA fragments (influenza virus nucleoprotein) , having a higher antigenic presentation efficiency compared to the analogues with the whole antigenic sequence, in DNA vaccination was reported (Anton L. C. et al . , J. Immunol . 158 : 2535, 1997) . Furthermore the processing of intracellular proteins and presentation of the respective peptides by MHC class I proteins in physiologic conditions, underlie the mechanism of immunological surveillance. For a given protein and a specific MHC context, there are peptide fragments termed dominants (i. e. prevailing on subdominants or cryptics) , which are unable to generate any immune response because they are recognized as "self". It has now been outlined, according to an aspect of the present invention, that an approach aimed at supporting the non- dominant epitope presentation by the administration of a mix of antigen protein fragments is able to elicit a surprising cytotoxic immune response. Description of the invention
It has now been found that DNA molecules, encoding fragments of a protein overexpressed in tumor cells, can be conveniently used to induce an antigen-specific anti-tumor immune response . The invention relates particularly to a pharmaceutical composition containing one or more DNA encoding Mucin (MUC-1) protein fragments .
The DNA used in the present invention can be plasmid or viral DNA, preferably plasmid DNA obtained employing the pMRS30 expression vector described in fig. 13.
The compositions according to the invention contain preferably at least two DNA fragments of the Mucin (MUC-1) or of another protein overexpressed in tumor cells.
The compositions according to the invention contain preferably at least four fragments, each ranging from 200 to about 700 nucleotides, each sequence being juxtaposed and possibly partially overlapping, from about 50 to about 150 nucleotides, at the 3' and/or 5' end of the adjacent one.
The DNA fragments according to the invention can be possibly preceded at the 5' end by a ubiquitin encoding DNA sequence and possibly also by a Lad portion of Escherichia coli .
The invention relates also to new DNA fragments and to the use of Mucin-1 fragments defined above in the medicine and anti- tumor vaccine preparation.
Description of the figures Fig. 1
Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS166 expression vector. This DNA includes the sequence corresponding to nucleotides 136-339 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by the two translation stop codons, TGA and TAA. The encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 136-339 fragment of the EMBL sequence J05581.
Fig. 2
Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS169 expression vector. This DNA includes the sequence corresponding to nucleotides 205-720 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 205-720 fragment of the EMBL sequence J05581.
Fig. 3
Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS168 expression vector. This DNA includes the sequence corresponding to nucleotides 631-1275 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 631-1275 fragment of the EMBL sequence J05581. Fig. 4
Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS167 expression vector. This DNA includes the sequence corresponding to nucleotides 1222-1497 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 1222-1497 fragment of the EMBL sequence J05581.
Fig. 5
Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS175 expression vector. This DNA includes the sequence corresponding to nucleotides 136-1497 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 136-1497 fragment of the EMBL sequence J05581.
Fig. 6
Nucleotide DNA sequence (with the respective amino acid sequence) termed UBILacI . The encoded polypeptide includes the ubiquitin sequence fused to a partial sequence of the bacterial protein beta-galactosidase, as described in Chau V. et al .
Science 243 : 1576, 1989.
Fig. 7 Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the expression vector pMRS30 to give the pMRS171 expression vector. This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence corresponding to nucleotides 136-339 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA. The coded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 136-339 of the EMBL sequence J05581. Fig. 8 Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS174 expression vector. This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 205-720 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 205-720 of the EMBL sequence J05581.
Fig. 9
Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS173 expression vector. This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 631-1275 of the EMBL sequence J05581 followed by two translation stop codons, TGA and
TAA. The encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 631-1275 of the EMBL sequence J05581.
Fig. 10
Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS172 expression vector. This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 1222-1497 of the EMBL sequence J05581 followed by two translation stop codons, TGA and
TAA. The encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 1222-1497 of the EMBL sequence J05581.
Fig. 11
Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS176 expression vector. This DNA includes the sequence named UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 136-1497 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA. The encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 136-1497 of the EMBL sequence J05581. Fig. 12
Electrophoretic analysis on 1% agarose gel in IX TBE. mRNA extracted from CHO, CD34+ dendritic cells and dendritic cells from PBMC, respectively, transfected with pMRS169, and subjected to RT-PCR reaction either with (lanes 4, 8, 12) or without (lanes 5, 9, 13) Reverse Transcriptase . Molecular weight DNA marker (lane 1); internal negative controls (lanes 2, 6); internal positive controls (lanes 3, 7, 10, 11); positive control from Promega kit (lane 14) . Fig. 13 Nucleotide sequence of the pMRS30 expression vector. The 1- 2862 region corresponds to the Accl (location 504) - BamHI (location 3369) region of the pSV2CAT vector (EMBL M77788) ; the 2863-3721 region includes the human cytomegalovirus promoter (human cytomegalovirus major immediate-early gene enhancer) ; the 3722-4905 region includes several cloning sites, including Xbal (location 3727) , and the processing signal of the rabbit beta- globin gene.
Detailed description of the invention
A DNA plasmid pool encoding, in eukaryotic cells, fragments of the MUC-1 human protein antigen was prepared. Constructs are based on the mammalian expression vector termed pMRS30, described in figure 13 and previously claimed in the Patent Application W095/11982, and contain partial sequences of the MUC-1 cDNAs reported in the EMBL database with accession number J05581. MUC-1 encoding DNA was fragmented so that each fragment represents a discrete portion, partially overlapping to the adjacent ones. Administration of a mix of such plasmids can cause different plasmids to transfect different APC cells at the administration site. Therefore such cells produce and process discrete portions of the MUC-1 protein giving the related peptides. In those conditions, the occurring subdominant and cryptic peptides can also be presented in association with class I MHC molecules thus generating a cytotoxic immune response. The present invention thus relates to the use of a group of four constructs (Figures 1 to 4) containing MUC-1 cDNA partial fragments in admixture containing at least two of them and a group of four constructs (Figures 7 to 10) containing MUC-1 cDNA partial fragment preceded by the DNA encoding a protein sequence containing Ubiquitin and an Escherichia coli Lac I portion (Figure 6) used separately or in admixture containing at least two of them.
The present invention relates also to the use of the construct (Figure 5) containing the almost complete sequence of the MUC-1 cDNA and the construct (Figure 11) containing the almost complete sequence of the MUC-1 cDNA preceded by the DNA encoding a protein sequence containing Ubiquitin and an Escherichia coli Lac I portion.
The mixture of the four constructs containing the partial fragments of the MUC-1 cDNA and the mixture of the four constructs containing the partial fragments of the MUC-1 cDNA preceded by the DNA encoding a protein sequence, containing Ubiquitin and an Escherichia coli Lac I portion, represents a preferred embodiment of the present invention. Constructs according to the present invention can be used in the anti-tumor therapy of patient affected with tumors characterized by high MUC-1 expression.
Constructs described in the present invention were obtained as follows. In the case of the first series of constructs, the fragments of the MUC-1 DNA were obtained by RT-PCR from BT20 cell line or by DNA partial chemical synthesis. Such fragments were then cloned into the pMRS30 expression vector and verified by sequencing. In the case of the second series of constructs, the fragments were obtained from the first series of constructs by a PCR re-amplification. These fragments were then fused to the DNA encoding the Ubiquitin (obtained by RT-PCR from MCF7 cell line mRNA) and a partial lad sequence (obtained by PCR from the commercial vector pGEX) . DNA sequences thus obtained were then cloned in the pMRS30 expression vector and verified by sequencing. For the intended therapeutic or prophylactic uses, fragments or constructs according to the invention are suitably formulated, using carriers and methods previously employed in naked DNA vaccines, as described for example in The Immunologist, 1994, 2:1; WO 90/11092, Proc . Natl. Acad. Sci . U.S.A., 1986, 83, 9551; US 5580859; Immunology today 19 (1998), 89-97); Proc. Natl. Acad. Sci. U.S.A. 90 (1993), 11478-11482; Nat. Med. 3 (1997), 526-532; Vaccine 12 (1994), 1495-1498; DNA Cell. Biol. 12 (1993), 777-783. The dosages will be determined on the basis of clinical and pharmacological-toxicological trials. Generally speaking, they will be comprised between 0.005 μg/kg and 5 μg/kg of the fragment mix. The composition of the invention can also contain a cytokine or a cytokine encoding plasmid.
The invention will be further illustrated by means of the following examples.
Example 1. Plasmid pMRSlββ construction. BT20 tumor cells (ATCC HTB-19) were cultured in Eagles MEM supplemented with 10% fetal calf serum. Ten million cells were trypsinized, washed with PBS, and mRNA extracted.
An aliquot of this RNA was subjected to RT-PCR (reverse transcriptase-polymerase chain reaction) reaction in the presence of the following synthetic oligonucleotides :
VI1 (5 GATCTCTAGAATGACAGGTTCTGGTCATGCAAGC 3) V4 (5 GATCTCTAGAAAGCTTATCAACCTGAAGCTGGTTCCGTGGC 3) The produced DNA fragment, purified and digested with the restriction enzyme Xbal, was cloned into the pMRS30 expression vector, containing the human cytomegalovirus promoter and the beta-globin polyadenylation signal as claimed in the Patent W09511982. The resulting pMRS166 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the nucleotides 136-339 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
This fragment is reported in fig. 1.
Example 2. Plasmid pMRS169 construction.
An aliquot of the RNA obtained as reported in example 1 was amplified by RT-PCR in the presence of the following synthetic oligonuclotides :
VI2 (5 GATCTCTAGAATGGTGCCCAGCTCTACTGAGAAGAATGC 3)
VI5 (5 GGCGGTGGAGCCCGGGGCTGGCTTGT 3)
The produced DNA fragment, purified and digested with the restriction enzymes Smal and Xbal, was fused, by the Smal restriction site, to a DNA fragment entirely synthetically constructed, and including a sequence partially corresponding to the nucleotides 457-720 of the EMBL sequence J05581 and two stop codons, TGA and TAA. The whole fragment was thus cloned in the Xbal site of the pMRS30 expression vector. The resulting pMRS169 vector contains a DNA fragment including the ATG codon, the sequence partially corresponding to the nucleotides 205-720 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
This fragment is reported in fig. 2. Example 3. Plasmid pMRS168 construction.
An aliquot of the RNA obtained as reported in example 1 was amplified by RT-PCR in the presence of the following synthetic oligonuclotides :
VI3 (5 GATCTCTAGAATGGGCTCAGCTTCTACTCTGGTGCACAACGGC 3) V8 (5 GATCTCTAGAAAGCTTATCACAAGGCAATGAGATAGACAATGGCC 3)
The produced DNA fragment, purified and digested with the restriction enzyme Xbal was cloned in the pMRS30 expression vector. The resulting pMRS168 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the nucleotides 631-1275 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
This fragment is reported in fig. 3.
Example 4. Plasmid pMRS167 construction. An aliquot of the RNA obtained as reported in example 1 was subjected to RT-PCR reaction in the presence of the following synthetic oligonucleotides :
VI4 (5 GATCTCTAGAATGCTGGTGCTGGTCTGTGTTCTGGTTGCGC 3)
VI0 (5 GATCTCTAGAAAGCTTATCACAAGTTGGCAGAAGTGGCTGC 3) The produced DNA fragment, purified and digested with the restriction enzyme Xbal was cloned in the pMRS30 expression vector. The resulting pMRS167 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the nucleotides 1222-1497 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
This fragment is reported in fig. 4.
Example 5. Plasmid pMRS175 construction. pMRS166, 169, 168, 167 plasmids were subjected to PCR reaction in the presence of the following nucleotide pairs: VI1 (see example 1)
VI8 (5 AACCTGAAGCTGGTTCCGTGGC 3) for pMRS166
VI9 (5 GTGCCCAGCTCTACTGAGAAGAATGC 3)
V20 (5 GCTGGGAATTGAGAATGGAGTGCTCTTGC 3) for pMRS169
V21 (5 GGCTCAGCTTCTACTCTGGTGCACAACGGC 3) V22 (5 CAAGGCAATGAGATAGACAATGGCC 3) for pMRS168
V23 (5 CTGGTGCTGGTCTGTGTTCTGGTTGCG 3)
VI0 (see example 4) for pMRS167
The four DNA fragments obtained in the respective PCR reactions were mixed in equimolar amounts and PCR reacted in the presence of the Vll and V10 oligonuclotides.
The produced DNA fragment, purified and digested with the Xbal restriction enzyme, was cloned in the pMRS30 expression vector. The resulting pMRS175 vector contains a DNA fragment including the ATG codon, the sequence partially corresponding to the nucleotides 136-1497 of the EMBL sequence J05581 and two stop codons TGA and TAA.
This fragment is reported in fig. 5.
Example 6. Plasmid pMRS171 construction. MCF7 tumor cells (ATCC HTB-22) were cultured in Eagles MEM supplemented with 10% fetal calf serum. Ten million cells were trypsinized, washed with PBS, and mRNA extracted.
An aliquot of this RNA was subjected to RT-PCR in the presence of the following synthetic oligonucleotides: UBIup (5GATCTCTAGAATGCAGATCTTCGTGAAGACCCTGACTGGT 3)
UBIdown (5TCAC(^GCGAGACGGGCAACAGCCATGCACCACTACCGTGCCTCCCACCTCTGAGACGGAGC ACCAGG 3)
The reaction produces a DNA fragment termed fragment 1. DNA from pGEXHT (Pharmacia) was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:
Laclup (5CCTCCGTCTCAGAGGTGGGAGGCACGGTAGTGGTGCATGGCTGTTGCCC
GTCTCGCTGGTGAAAAG 3)
LacIdown (5GATCGGATCCTCGGGAAACCTGTCGTGCCAGCTGC 3) This reaction gives a DNA fragment termed fragment 2.
The 1 and 2 DNA fragments, obtained in the respective PCR reactions, were mixed in equimolar amounts and subjected to PCR reaction in presence of the UBIup and Lacldown oligonucleotides.
The produced DNA fragment, purified and digested with the restriction enzymes Xbal and BamHI, was cloned into the pUClδ commercial plasmid. The resulting pMRS156 vector contains a DNA fragment including the sequence encoding the ubiquitin fused to the sequence encoding a bacterial beta-galactosidase portion. This fragment, termed UBILacI, is reported in fig. 6. Plasmid pMRS166 DNA was subjected to a PCR reaction in presence of the following synthetic oligonucleotides: V3 (5GATCGGATCCACAGGTTCTGGTCATGCAAGC 3) V4 (see Example 1) The produced DNA fragment, purified and digested with the restriction enzymes Xbal and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from the pMRS156 plasmid. The resulting fragment was cloned into the pMRS30 expression vector. The resulting pMRS171 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 136-339 nucleotides of the EMBL sequence J05581 and two stop codons, TGA and TAA. This fragment is reported in fig. 7.
Example 7. Plasmid pMRS174 construction. Plasmid pMRS169 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides: V5 (5GATCGGATCCGTGCCCAGCTCTACTGAGAAGAATGC 3) V6 (5GATCTCTAGAAAGCTTATCAGCTGGGAATTGAGAATGGAGTGCTCTTGC 3) The produced DNA fragment, purified and digested with the restriction enzymes Xbal and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from the pMRS156 plasmid. The resulting fragment was cloned into the pMRS30 expression vector. The resulting pMRS174 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 205-720 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 8.
Example 8. Plasmid pMRS173 construction.
Plasmid pMRS168 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:
V7 (5GATCGGATCCGGCTCAGCTTCTACTCTGGTGCACAACGGC 3) V8 (see example 3)
The produced DNA fragment, purified and digested with the restriction enzymes Xbal and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from the pMRS15β plasmid. The resulting fragment was cloned into the pMRS30 expression vector. The resulting pMRS173 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 631-1275 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 9.
Example 9. Plasmid pMRS172 construction.
Plasmid pMRS167 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:
V9 (5 GATCGGATCCCTGGTGCTGGTCTGTGTTCTGGTTGCGC 3)
VI0 (see example 4)
The produced DNA fragment, purified and digested with the restriction enzymes Xbal and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from pMRS156 plasmid. The resulting fragment was cloned into the pMRS30 expression vector. The resulting pMRS172 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 1222-1497 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 10.
Example 10. Plasmid pMRS176 construction.
Plasmid pMRS167 DNA was subjected PCR reaction in the presence of the following synthetic oligonucleotides: V3 (see example 6)
VI0 (see example 4)
The produced DNA fragment, purified and digested with the restriction enzymes Xbal and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from pMRS156 plasmid. The resulting fragment was cloned into the PMRS30 expression vector. The resulting pMRS176 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 136-1497 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 11.
Example 11. Eukaryotic cell transfection and testing for transcriptio .
CHO (Chinese Hamster Ovary) cells were cultured in alpha MEM supplemented with ribonucleotides and deoxyribonucleotides at transfection time.
Dendritic cells were obtained from CD34+ hemopoietic precursors cultured in IMDM without serum, supplemented with GM- CSF, IL4, SCF, Fit3 and TNFalpha. After 7 days the obtained cell population was transfected.
Dendritic cells were obtained from monocytes isolated from PBMC (peripheral blood mononuclear cells) , cultured in RPMI supplemented with FCS, GM-CSF, and IL-4. After 7 days the obtained cell population was transfected. In each case, about one million cells were transfected with one of the plasmids reported in examples 1 to 10. Transfection was carried out using 3 μg of plasmid DNA and 4 μl of DMRIE (Gibco) by lipofection.
After 24 hours cells were harvested, washed with PBS and lysed in order to extract the mRNA.
A mRNA aliquot was subjected to RT-PCR reaction in the presence of the oligonucleotide pair specific for the transfected DNA plasmid.
This experiment was carried out for each plasmid reported in the examples 1 to 10, using the following oligonucleotide pairs: V11/V4 for pMRS166, V12/V6 for pMRS169, V13/V8 for pMRS168, V4/V10 for pMRS167, V4/V10 for pMRS175, UBIup/V4 for pMRS171, UBIup/V6 for pMRS174, UBIup/V8 for pMRS173, UBIup/VIO for pMRS172, V14/V10 for pMRS176. As a representative example, figure 12 reports the electrophoretic analysis of the DNA fragments obtained by RT-PCR from the mRNA of the three cell populations, transfected with the pMRS169 plasmid. In this case the oligonucleotide pair V12/V6 was used. Example 12. In vivo study results.
In the in vivo studies, the mixtures of the four fragments and the pMRS30 plasmid (vector without insert and thus used as a negative control) were used. In order to test the occurred immunization, an ELISA test was used to show the human mucin specific antigens .
The in vivo studies were conducted using human MUCl transgenic C57BL mice. As a consequence in these animals the MUCl protein represents a self-protein. The employed vaccination schedule consists of 3 intradermic (dorsal portion, 50 micrograms DNA for each side) administrations (at days 0, 14, 28) of 100 micrograms plasmid DNA. At day 14 after the last administration, the animals were sacrificed and sera were tested for anti-human mucin antibodies. The assayed fragment mixes, object of the present invention, stimulated a good immune response in the treated animals.
On the other hand, vaccination experiments with a 60- aminoacid peptide corresponding to the 20 aminoacids reported in fig. 2, from location 86 to location 105, repeated three times (this peptide is termed 3XTR) , were also carried out.
The two vaccinations differ in the type of the elicited antibody response. The antibody titer results much more higher in the vaccination with 3XTR. Furthermore the noticed IgG subtypes are in favor of an essentially humoral (antibody) response in the case of vaccination with 3XTR, and of a cellular response (cytotoxic) in the case of vaccination with DNA. For anti-tumor therapy, a principally cytotoxic immune response is preferable. Because the experiments were carried out on transgenic mice, in whom the human mucin is "self", we can foresee a similar response in humans. This response could justify the use, as DNA vaccines, of the compounds of the present invention in the treatment of MUCl overxpressing human tumors .

Claims

1. Pharmaceutical composition containing one or more DNA molecules, encoding fragments of a protein overexpressed in tumor cells in order to induce an antitumor Ag-specific immune response, in combination with suitable excipients and adjuvants.
2. Pharmaceutical composition according to claim 1 wherein the overexpressed protein is MUC-1.
3. Pharmaceutical composition according to claim 1 or 2 containing at least two DNA molecules each containing a cDNA sequence encoding a Mucin fragment (MUC-1) .
4. Composition according to claim 3 containing at least three DNA molecules each containing a cDNA sequence encoding a Mucin fragment (MUC-1) .
5. Composition according to claim 4 containing at least four DNA molecules each containing a cDNA sequence encoding a Mucin fragment (MUC-1) .
6. Composition according to claims 3, 4 or 5 wherein the DNA sequences comprise about 200 to about 700 nucleotides, each sequence being contiguous and possibly partially overlapping, from about 50 to about 150 nucleotides at the 3' and/or 5' end, to the adjacent one .
7. Pharmaceutical composition according to any claim from 2 to 6 wherein the used mixture consists of, at least, two plasmid DNA molecules, each containing a DNA fragment selected from those whose sequences are described in figures 1, 2, 3, and 4.
8. Pharmaceutical composition according to claim 7 wherein the used mixture consists of the pool of plasmid DNA molecules, where each molecule contains a DNA fragment selected from those whose sequences are described in figures 1, 2, 3, and 4.
9. Pharmaceutical composition according to claim 1 or 2 wherein a plasmid DNA molecule containing the sequence described in figure 5 is used.
10. Pharmaceutical composition according to claims 7, 8, or 9 wherein the used plasmid DNA molecules derive from the fusion of the pMRS30 expression vector in Fig. 13 to each sequence described in figures 1, 2, 3, 4, 5.
11. Pharmaceutical composition according to claims 2 to 6 wherein the used sequences, corresponding to single fragments of the protein, are preceded in the 5 ' termini by the sequence described in Fig. 6 encoding the ubiquitin and a La portion from Escherichia Coli.
12. Pharmaceutical composition according to claim 11 wherein the mixture consists of one or more sequences deriving from joining the pMRS30 expression vector, described in Fig. 13, to a DNA sequence selected from those described in figures 7, 8, 9, and 10.
13. Pharmaceutical composition according to claim 11 wherein the mixture consists of the totality of the sequences deriving from joining the pMRS30 expression vector to a DNA sequence selected from those described in figures 7, 8, 9, and 10.
14. Pharmaceutical composition according to claim 11 wherein the mixture consists of a sequence deriving from joining the pMRS30 expression vector to the sequence described in figure 11.
15. Pharmaceutical composition according to any preceding claims, further containing a cytokine or a cytokine encoding plasmid.
16. A plasmid DNA molecule consisting of the pMRS30 expression vector joined to a DNA sequence, encoding a MUC-1 protein fragment and whose sequence is selected from the group of those described in figures 1, 2, 3, 4, and 5.
17. A DNA molecule encoding a protein MUC-1 fragment preceded in its 5' terminus by the sequence described in Fig. 6.
18. A DNA molecule according to claim 17 selected from those described in figures 7, 8, 9, 10, and 11.
19. A plasmid DNA molecule obtained by joining the pMRS expression vector to a DNA molecule selected from those of claim 17 or 18.
20. Use of DNA molecules of claims 16-19 in the preparation of a composition with anti-tumor effect.
PCT/EP1999/007874 1998-10-30 1999-10-18 Dna molecules encoding muc-1 and use thereof in tumor vaccination WO2000025827A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2000579265A JP2002528519A (en) 1998-10-30 1999-10-18 Pharmaceutical composition containing DNA encoding an antigenic protein having antitumor effect
BR9914892-7A BR9914892A (en) 1998-10-30 1999-10-18 Pharmaceutical composition, containing fragments of a DNA encoding antigenic protein with antitumor effect
EA200100395A EA200100395A1 (en) 1998-10-30 1999-10-18 PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING ANTIGENIC PROTEIN COATING ANTI-ANTITROTHAL EFFECT
PL99348156A PL348156A1 (en) 1998-10-30 1999-10-18 Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect
AU11522/00A AU1152200A (en) 1998-10-30 1999-10-18 Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect
CA002348745A CA2348745A1 (en) 1998-10-30 1999-10-18 Dna molecules encoding muc-1 and use thereof in tumor vaccination
HU0103784A HUP0103784A2 (en) 1998-10-30 1999-10-18 Dna molecules encoding muc-1 and use thereof in tumor vaccination
SK571-2001A SK5712001A3 (en) 1998-10-30 1999-10-18 Pharmaceutical composition
MXPA01004186A MXPA01004186A (en) 1998-10-30 1999-10-18 Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect.
EP99971329A EP1124956A2 (en) 1998-10-30 1999-10-18 Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect
BG105458A BG105458A (en) 1998-10-30 2001-04-20 Dna molecules encoding muc-1 and use thereof in tumor vaccination

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI98A002330 1998-10-30
IT1998MI002330A IT1303683B1 (en) 1998-10-30 1998-10-30 PHARMACEUTICAL COMPOSITION WITH ANTI-TUMORAL ACTION CONTAINING DNACODIFIER FOR FRAGMENTS OF AN ANTIGENIC PROTEIN.

Publications (2)

Publication Number Publication Date
WO2000025827A2 true WO2000025827A2 (en) 2000-05-11
WO2000025827A3 WO2000025827A3 (en) 2000-08-10

Family

ID=11380969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007874 WO2000025827A2 (en) 1998-10-30 1999-10-18 Dna molecules encoding muc-1 and use thereof in tumor vaccination

Country Status (19)

Country Link
EP (1) EP1124956A2 (en)
JP (1) JP2002528519A (en)
CN (1) CN1324406A (en)
AR (1) AR020927A1 (en)
AU (1) AU1152200A (en)
BG (1) BG105458A (en)
BR (1) BR9914892A (en)
CA (1) CA2348745A1 (en)
CO (1) CO5231134A1 (en)
CZ (1) CZ20011521A3 (en)
EA (1) EA200100395A1 (en)
HU (1) HUP0103784A2 (en)
IT (1) IT1303683B1 (en)
MX (1) MXPA01004186A (en)
PE (1) PE20001287A1 (en)
PL (1) PL348156A1 (en)
SK (1) SK5712001A3 (en)
TR (1) TR200101141T2 (en)
WO (1) WO2000025827A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
WO2002022685A3 (en) * 2000-09-11 2002-09-26 Donald W Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
WO2005042573A1 (en) * 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
US7696306B2 (en) * 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
US7745109B2 (en) 2000-12-22 2010-06-29 Dana-Farber Cancer Insitute, Inc. Regulation of cell growth by MUC1
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2343195C2 (en) * 2003-03-24 2009-01-10 Дзе Скриппс Рисерч Инститьют Dna-vaccine against tumoral growth and ways of their application
CN106279435B (en) * 2016-08-16 2019-06-07 新乡医学院 Target anti-tumor vaccine, encoding gene, expression vector, expression engineering bacteria and the application of VEGF and mucin1
CN114230655A (en) * 2021-03-24 2022-03-25 深圳市新靶向生物科技有限公司 Antigenic peptide combination related to esophageal cancer driver gene mutation and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011982A1 (en) * 1993-10-25 1995-05-04 Menarini Ricerche Sud S.P.A. Expression system for eukaryotic cell lines
WO1998037095A2 (en) * 1997-02-24 1998-08-27 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011982A1 (en) * 1993-10-25 1995-05-04 Menarini Ricerche Sud S.P.A. Expression system for eukaryotic cell lines
WO1998037095A2 (en) * 1997-02-24 1998-08-27 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANTON ET AL: "MHC CLASS I-ASSOCIATED PEPTIDES PRODUCED FROM ENDOGENOUS GENE PRODUCTS WITH VASTLY DIFFERENT EFFICICIENCES" THE JOURNAL OF IMMUNOLOGY, vol. 158, 1997, pages 2535-2542, XP002136996 cited in the application *
CHAU V ET AL: "A MULTIUBIQUITIN CHAIN IS CONFINED TO SPECIFIC LYSINE IN A TARGETED SHORT-LIVED PROTEIN" SCIENCE (WASHINGTON D C) 1989, vol. 243, no. 4898, 1989, pages 1576-1589, XP002136993 ISSN: 0036-8075 cited in the application *
GENDLER S J ET AL: "MOLECULAR CLONING AND EXPRESSION OF HUMAN TUMOR-ASSOCIATED POLYMORPHIC EPITHELIAL MUCIN" JOURNAL OF BIOLOGICAL CHEMISTRY 1990, vol. 265, no. 25, 1990, pages 15286-15293, XP002136995 ISSN: 0021-9258 *
GRAHAM R A ET AL: "The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine" CANCER IMMUNOLOGY AND IMMUNOTHERAPY,DE,BERLIN, vol. 2, no. 42, 1 January 1996 (1996-01-01), pages 71-80, XP002075466 ISSN: 0340-7004 *
GRANT ETHAN P ET AL: "Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation." JOURNAL OF IMMUNOLOGY 1995, vol. 155, no. 8, 1995, pages 3750-3758, XP002136994 ISSN: 0022-1767 cited in the application *
RODRIGUEZ FERNANDO ET AL: "DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction." JOURNAL OF VIROLOGY 1997, vol. 71, no. 11, 1997, pages 8497-8503, XP002136992 ISSN: 0022-538X cited in the application *
See also references of EP1124956A2 *
TAYLOR-PAPADIMITRIOU J AND EPENETOS A A: "Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy" TIBTECH,GB,CAMBRIDGE, no. 12, 1 January 1994 (1994-01-01), pages 227-233, XP002075467 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
WO2002022685A3 (en) * 2000-09-11 2002-09-26 Donald W Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
US7745109B2 (en) 2000-12-22 2010-06-29 Dana-Farber Cancer Insitute, Inc. Regulation of cell growth by MUC1
US7696306B2 (en) * 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
US8193309B2 (en) 2003-07-11 2012-06-05 Board Of Regents Of The University Of Nebraska Compositions and methods for preventing or treating cancer
US8653233B2 (en) 2003-07-11 2014-02-18 University Of Nebraska Medical Center Compositions and methods for preventing or treating cancer
WO2005042573A1 (en) * 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3

Also Published As

Publication number Publication date
JP2002528519A (en) 2002-09-03
HUP0103784A2 (en) 2002-02-28
ITMI982330A1 (en) 2000-04-30
CN1324406A (en) 2001-11-28
ITMI982330A0 (en) 1998-10-30
CA2348745A1 (en) 2000-05-11
SK5712001A3 (en) 2002-04-04
AR020927A1 (en) 2002-06-05
MXPA01004186A (en) 2002-06-04
CO5231134A1 (en) 2002-12-27
BR9914892A (en) 2001-07-17
PE20001287A1 (en) 2000-12-07
IT1303683B1 (en) 2001-02-23
TR200101141T2 (en) 2001-09-21
CZ20011521A3 (en) 2001-10-17
BG105458A (en) 2002-06-28
EA200100395A1 (en) 2001-10-22
EP1124956A2 (en) 2001-08-22
PL348156A1 (en) 2002-05-06
AU1152200A (en) 2000-05-22
WO2000025827A3 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
US7446185B2 (en) Her2/neu target antigen and use of same to stimulate an immune response
Tüting et al. Gene-based strategies for the immunotherapy of cancer
EP1658097B1 (en) Nucleotide and cellular vaccine composition
Schultz et al. Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA
Kim et al. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine
WO2019101062A9 (en) Recombinant vaccine and application thereof
EP1124956A2 (en) Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect
KR101810840B1 (en) Msi-specific framshift peptides (fsp) for prevention and treatment of cancer
RU2303069C2 (en) Muc1 antigen with reduced number of repeated vntr-units
Restifo et al. Enhancing the recognition of tumor associated antigens
AU776795B2 (en) Chorionic gonadotropin DNA vaccines and methods
Santin et al. Development and characterization of an IL-4-secreting human ovarian carcinoma cell line
US20070042047A1 (en) Vaccines
US20060062798A1 (en) Vaccines
WO1998015285A9 (en) Methods and compositions for inducing a protective immune response to cancers
CA2460809A1 (en) Polynucleotide vaccine
Clary et al. Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system
Moelling et al. Development of a DNA Vaccine Againts Malignant Melanoma
JP2010502176A (en) Synthetic gene
MXPA99012024A (en) Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment
AU2002244196A1 (en) Tri-hybrid melanoma antigen

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99812745.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 11522

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 1999 105458

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004186

Country of ref document: MX

Ref document number: 2001/01141

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2348745

Country of ref document: CA

Ref document number: 2348745

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 579265

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09830513

Country of ref document: US

Ref document number: 5712001

Country of ref document: SK

Ref document number: IN/PCT/2001/591/CHE

Country of ref document: IN

Ref document number: 1999971329

Country of ref document: EP

Ref document number: PV2001-1521

Country of ref document: CZ

Ref document number: 200100395

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999971329

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-1521

Country of ref document: CZ

CFP Corrected version of a pamphlet front page

Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWR Wipo information: refused in national office

Ref document number: PV2001-1521

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999971329

Country of ref document: EP